Lybrate, India's Answer to Chunyu Doctor, Files for IPO After $10.2M Funding Round
Events and Perspectives
The most painful thing in life is not that you are alive but your money is gone. It is that you are alive,
Yet it was never destined to make headlines.
Yet others can do so with ease. Take, for example, “Spring Rain Doctor.”
However, this Chunyu Yisheng is not the same as that Chunyu Yisheng. It isIndia’s “Chunyu Doctor”: Lybrate. The key is that this medical platform enables patients to communicate anonymously with doctors anytime and anywhere via the app and online channels. This is because openly discussing health issues is considered taboo in India. According to VCBeat, Lybrate launched its medical platform this January. In addition, the Lybrate app alsoThere is a Health Feed feature, which provides services similar to a community forum. It offers health tips categorized by different medical specialties. Under each health tip, there are 400 further subdivided topics, allowing users to access content based on their interests.。
To date, they have recruited over 80,000 doctors across India, with more than 500,000 downloads and over 100,000 daily patient visits. AndRecently Secured $10.2 Million in Investment, with investors including Tiger Global, Nexus, and Ratan Tata. Lybrate stated that it would use this investment to recruit talent, optimize technology, and expand operations.
Unlike online,Offline, a “Medical Night Market” Emerges。
What's going on?
To alleviate the difficulty of accessing medical care, where patients would register in the morning only to be seen in the afternoon, some municipal-level hospitals in Shenyang have launched “Medical Night Markets,” allowing patients to consult with specialists during evening hours.
Unlike emergency departments, which primarily treat patients with critical and life-threatening conditions, medical night clinics offer services in internal medicine, surgery, pediatrics, dermatology, and other specialties, staffed by experienced specialists. Supporting services, including diagnostic tests and pharmacy operations, are fully synchronized to ensure seamless care. This model challenges the public perception that hospitals only provide emergency services at night. Currently, municipal-level hospitals such as Shenyang No. 7 People’s Hospital and Shenyang Children’s Hospital have launched these medical night clinics.
Alright, let’s chat about some life gossip.
"It is said that the medicine delivery person and the food delivery person have started a relationship."
In fact, here’s what happened. Last week, after Renhe Group announced its strategy to build the “Dingdang Big Health Ecosystem,”Dingdang Medicine Takes the Lead by Partnering with Meituan Waimai, the Largest Food Delivery Platform. It is understood that, as part of this strategic cooperation, Dingdang Kuaiyao will integrate 400 pharmacies across 10 cities in China, offering over 10,000 pharmaceutical products spanning six major categories: Western and Chinese medicines, Chinese herbal decoction pieces, nutritional supplements, adult products, medical devices, and personal care items. By the end of this year, Dingdang Kuaiyao aims to cover first- and second-tier cities nationwide, partnering with nearly 10,000 pharmacies and serving hundreds of millions of users, thereby enabling more users to experience fast and professional services free of charge.
Additionally, three other pairs joined hands last week.
GSK Partners with Apple ResearchKit。
According to the latest news from Firstword Pharma, GlaxoSmithKline (GSK) and Purdue Pharma will leverage Apple’s ResearchKit framework for drug development. In its statement, GSK indicated that its primary focus in the coming months will be on integrating ResearchKit data into clinical trials. This collaboration with Apple represents an optimal opportunity for major pharmaceutical companies to collect patient data.
In addition, Larry Pickett, Chief Information Officer of Purdue Pharma, known for its OxyContin painkiller, stated that the company is seeking to apply this tool to data collection in research and development.
Undoubtedly, the impact of technological power on healthcare is becoming increasingly significant, although it remains unclear exactly how it influences healthcare. But...
Next,Personal Health Coaching App Vida and Pharmaceutical Manufacturers。
Last week, Vida partnered with pharmaceutical giant AstraZeneca to launch “Day-by-Day,” a program specifically designed for heart disease patients. This jointly developed Day-by-Day app guides cardiac patients in using the Vida Coach service. While Vida’s coaching typically costs $49 per month, AstraZeneca reinvests this revenue by rewarding users who complete hospital check-ups, participate in health organization activities, or meet specified health benchmarks. Although the majority of Vida’s user base seeks weight loss support—which remains its primary market focus—Vida has recently collaborated with Daily Burn, attracting a broader influx of users aiming to improve their physique or seeking weight-loss guidance.
Additionally,Yuwell Partners with Pfizer。
Last week, Yuwell Medical announced that it had signed a Strategic Cooperation Framework Agreement with Pfizer Investment. Under the agreement, Yuwell Medical and Pfizer Investment will engage in comprehensive cooperation in areas such as health management for chronic diseases including cardiovascular and cerebrovascular conditions and hypertension, research and development as well as application of integrated pharmaceutical-device products, expansion of internet-based health services, and online sales of pharmaceuticals and medical devices, all in compliance with relevant Chinese regulations. Both parties will jointly promote their brands in health service-related market activities and give priority to collaborating on new health management projects and supporting initiatives involving pharmaceuticals and medical devices.
This Love Agreement shall be effective for a term of three years, from July 16, 2015 to July 15, 2018. Upon expiration, the parties may extend the term by mutual agreement in writing.
"Public displays of affection are done; now let's look at the wealth-flaunting."
Last week,LeEco Makes RMB 15 Million Strategic Investment in Beijing Yidong Sib。
This marks another move by LeEco following its announcement earlier this month of a partnership with Winning Health Technology Group, a developer of medical information management systems, to jointly launch a health channel, healthcare applications, and cloud platforms, thereby entering the healthcare sector. This time, LeEco has joined forces with its subsidiary LeSports to make a strategic investment in Beijing Yidong Sibo Network Technology Co., Ltd., positioning itself in the community-based O2O and sports wellness sectors. The company also stated that LeSports and Yidong will collaborate in the future to create super products that comprehensively meet the needs of the sports-active population.
According to VCBeat, LeEco invested RMB 10 million from its own funds in this round, while LeSports contributed RMB 5 million. Together, the two entities hold a 60% stake in Yidong.
In addition to investments, there is also fundraising.
Vation Holdings announced that it plans to privately place no more than 120 million shares to raise up to RMB 1.377 billion, which will be used to invest in two projects: the “Primary Healthcare and Family Doctor Service Platform Construction Project” and the “Working Capital Replenishment Project.”
According to the preliminary plan, the price for this private placement will be no less than 90% of the average trading price of the company’s shares over either the 20 trading days preceding the first day of the issuance period or the immediately preceding trading day. The placement will be offered to no more than five specific investors. The plan indicates that the funds raised will be primarily used for the construction of a grassroots healthcare and family doctor service platform, with an estimated investment of approximately RMB 1.267 billion. It is understood that Wavetec will create a closed-loop business model—“village doctor consultations and health management + medical services for left-behind elderly and children + remote health monitoring by migrant family members via mobile applications”—by distributing portable medical diagnostic devices to village doctors in target expansion areas, establishing a cloud-based medical platform, and developing mobile applications.
"While you are still fundraising," it said,
It is about to start generating revenue.
This guy is Meiyou.Meiyou stated that it has successfully connected with over 2,000 female-oriented lifestyle service providers in sectors such as apparel, home goods, maternal and infant products, and food.. It also disclosed the latest user data: as of July 2015, the total number of users had exceeded 100 million, with 5 million daily active users.It also marked the first direct response to the product’s commercialization strategy, with a future focus on building an integrated closed-loop model of “tools + community + e-commerce.”。
Furthermore,Another revenue generator is the smart running shoe jointly developed by Xiaomi and Li-Ning.
In March this year, Xiaomi and Li-Ning reached a cooperation agreement to create smart running shoes with “ultra-high cost-performance,” which have now finally been launched. Last week, as Huami Technology, an ecosystem company under Xiaomi, officially unveiled the “Huami Smart Chip,” Li-Ning’s new running shoe models—Liejun and Chitu (Smart Edition)—equipped with this technology were also introduced. According to VCBeat, the Huami Smart Chip utilizes state-of-the-art low-power sensors, enabling a battery life of over one year even if the user runs a half-marathon daily. In terms of pricing, the Liejun and Chitu are priced at RMB 399 and RMB 199, respectively, with the former going on sale in China first today.
The last point that must be mentioned...
Long-rumored information has finally become a fact,Co-founders of Yihaodian, Yu Gang and CEO Liu Junling, have resigned。
Reports indicate that Yu and Liu will divest all their shares in Yihaodian.and decided to enter the pharmaceutical e-commerce industry。
VCBeat Exclusive
China’s First Nephrology Physician Group Debuts: Secures Hundreds of Millions in Financing
Baidu Doctor Aims to Become the Premier Gateway Connecting Patients and Healthcare Providers
Exclusive: Doctor Tool App Xingren Doctor Secures 200 Million Yuan in Series B Funding
How Did the Clinical Decision Support System UpToDate Become the Global No. 1?
How Teladoc, the First Publicly Listed Online Consultation Company, Crafted Its Narrative Back Then
The notions of “death at Series A” or “death at Series B” are false premises; the greatest risk may well be the angel investment firm that backs you.
Blueprint Health Adds 8 New Members to Its Startup Accelerator Program
New Technology |SnoreTech: Stay Away from the "Nighttime Killer" for a Snore-Free Sleep
New Technology |SmartCardio: A Monitor That Can Measure ECG During Exercise
New Technologies |ArterialScan: Artery Scanning Goes Fashionable—Measure with Just a Wear!
Artery Morning Brief: Fitbit Counters Jawbone’s Repeated Lawsuits, “We Just Happen to Be Selling Wearables Now”
VCBeat Morning Brief: YaoGeili Attracts Interest from Three Major Giants, Including Baidu Waimai, Within One Month; Second-Generation Google Glass Makes a Bold Debut!
VCBeat Morning Brief: World’s Largest Genealogy Website Ancestry.com Launches Health Database AncestryHealth
Decoding the Trending English Terms in Internet Healthcare:Connected Health/Population Health
Healthcare Reform
Shanghai Takes the Lead in Pension System Unification, with Contribution Standards Yet to Be Clarified:Following the nationwide release of documents on the unification of pension systems and occupational annuities, Shanghai has become the first city to issue supporting implementation plans. According to Shanghai’s regulations, the city will establish a basic old-age insurance system that combines social pooling with individual accounts, consistent with that for enterprise employees, with contributions made jointly by employers and employees. The policy adopts a transitional approach: existing retirees (“old persons”) will retain their original benefit standards; new entrants joining government agencies and public institutions after the reform (“new persons”) will have their basic pensions and individual account pensions calculated based on the principles of “higher contributions yield higher benefits” and “longer contribution periods yield higher benefits”; and those in between (“middle persons”) will transition gradually under a phased calculation method. However, the specific contribution rates for basic old-age insurance have not yet been clarified, while occupational annuity standards align with national guidelines.
CFDA Releases "Rules for the Classification of Medical Devices":The China Food and Drug Administration (CFDA) issued the "Rules for the Classification of Medical Devices," which came into effect on January 1, 2016. The Rules primarily made the following revisions and improvements: First, the term "registration category" for medical devices was changed to "management category" to clarify that this classification serves not only registration purposes but also relates to production, supervision, and other aspects. Second, it explicitly states that medical devices are classified based on their risk levels. The risk level of a medical device shall be comprehensively determined according to its intended purpose, taking into account factors such as structural characteristics, mode of use, conditions of use, and whether it comes into contact with the human body. Third, relevant classification scenarios were revised, supplemented, and improved; for instance, modes of use such as "implantable devices" and "standalone software" were added. Fourth, the principles for determination were refined, supplemented, and improved by listing twelve special classification principles. For example, special classification principles were established for products such as device kits, drug-device combination products, medical devices provided in sterile form, and medical devices used for the treatment of specific diseases. Fifth, terminology and definitions were revised; for instance, the descriptions of "invasive devices" and "implantable devices" were detailed, and explanations were added for terms such as "skin," "body orifices/cavities," "wound," "tissue," "blood circulatory system," "central nervous system," "medical devices with metrological measurement functions," and "chronic wounds." Sixth, it clarified that analyses and evaluations of changes in medical device risks should be conducted timely based on production, distribution, and usage conditions, and the Catalogue of Medical Devices should be adjusted accordingly. Seventh, it explicitly stated that the CFDA may organize the Medical Device Classification Expert Committee to formulate and adjust the Catalogue of Medical Devices. Eighth, it clarified that in vitro diagnostic reagents are classified in accordance with relevant regulations. Ninth, it specified that the classification of medical devices applies the Classification Determination Table; in cases involving special circumstances, the corresponding special classification principles shall also apply. The Classification Determination Table in the annex was adjusted accordingly based on the revisions to the main text.
Data
Increasing Payment Pressure on Medical Insurance Funds: Reserves in Multiple Provinces Deviate from the Red LineThe "Annual Report on the Development of China's Social Insurance (2014)," released by the Ministry of Human Resources and Social Security, shows that in 2014, medical expenses for employees covered by basic medical insurance amounted to RMB 708.3 billion, an increase of RMB 421.8 billion from 2009, with an average annual growth rate of nearly 20%. Against the backdrop of rapidly rising medical costs, medical insurance funds are facing increasing payment pressures, with pooled fund balances in multiple provinces deviating from the red line of "meeting six to nine months of payment needs."
The Global Market Value of Advanced Patient Monitoring Devices Reaches $31.4 Billion This Year:According to a Kalorama Information report, the global market for advanced patient monitoring systems is currently valued at $31.4 billion. This growth is driven by the shift in the patient monitoring market from traditional healthcare facilities and home-care settings toward wireless systems. Products involved include video and audio systems for clinician-patient communication, wireless communication systems for analyzing large volumes of patient data, handheld and mobile monitoring devices, and technologies that enable web-based access to patient records and convert data into electronic health records (EHRs).
2015 Consumer Health Habits Survey:According to the 2015 Consumer Health Habits Survey Report released by Kantar Media, 61% of adults purchase prescribed medications after visiting a doctor; 18% of consumers buy medical supplies online, and 20% prefer to compare prices of health products and services online. Furthermore, over the past six months, the three most popular health management apps were those for: exercise/fitness; calorie counting/diet control; and nutrition/healthy food pairing.
New Technologies
Diagnosing Depression Through Mobile Phone Usage Time and Location Data
Research conducted by a team at Northwestern University’s Feinberg School of Medicine demonstrates that smartphone data can identify individuals with depressive symptoms with an accuracy rate of up to 87%. Tracking screen time and location data provides insights into users’ psychological states. Individuals who spend more time on their phones are at a higher risk of depression. On average, individuals with depression use their smartphones for approximately 68 minutes per day, whereas healthy individuals average only 17 minutes. Furthermore, GPS tracking reveals that individuals who spend more time at home or exhibit minimal variation in location data are more likely to display symptoms of depression.
First Portable DNA Sequencing Device Debuts with Up to 6 Hours of Battery Life
Researchers at Orlando University in New Zealand have developed a wireless DNA sequencing device that is only the size of an ordinary laptop. Known as “Freedom 4,” this device sequences DNA samples using quantitative polymerase chain reaction (qPCR) technology. Notably, the Freedom 4 offers a battery life of up to six hours. It connects via a built-in wireless module to smartphones or laptops, enabling real-time transmission of sequencing data and facilitating DNA analysis through a dedicated application.
In addition to complex DNA sequencing, the Freedom 4 device can perform clinical diagnostics for various acute diseases and may even be applied to forensic examinations and environmental monitoring in the future.
Scientific Reports: PAMmography for Breast Cancer Detection
Researchers at the University of Twente in the Netherlands have developed a new technique for detecting breast cancer, named PAMmography. Based on the principles of photoacoustics, this technology utilizes short-pulse light to generate ultrasound waves in areas with high vascular density, such as those near malignant tumors. The study revealed specific characteristics of breast tumors, and the researchers employed this novel technique to perform specific imaging of these lesions.
A Strain Sensor That Tracks Human Body Movements Through Stretching
Higashi Kagaku has developed a stretchable strain sensor called “C-STRETCH.” It can detect the degree of elongation in terms of length and surface area. Due to its high flexibility and significant extensibility, it can be adhered to any curved surface. The company claims that it causes minimal discomfort even when worn on the body.
UK Researchers Develop Novel Laser-Based Sensor for Blood Glucose Monitoring
Researchers at the University of Leeds in the UK have recently developed a novel device that promises to address the challenges faced by diabetes patients in monitoring blood glucose levels. Utilizing low-energy laser technology, the device enables convenient, non-invasive detection of blood glucose values, eliminating the cumbersome procedures associated with traditional blood testing. Patients simply need to place their finger on the device for a scan to promptly obtain their blood glucose readings, with the entire process taking less than 30 seconds.
A "Super Cool" Antidepressant Device: Fisher Wallace
This product, like similar brain stimulators, uses transcranial microcurrent stimulation therapy to treat depression, anxiety, insomnia, and even pain. The manufacturer claims that “the entire device looks cool and fun!”
"Uh... Well, if the goal was to steer depression patients toward the path of Erlang Shen, congratulations—you’ve succeeded."
Capital
